McDermott Represents Portage Biotech in Tarus Therapeutics Acquisition - McDermott Will & Emery

McDermott Represents Portage Biotech in Tarus Therapeutics Acquisition


International law firm McDermott Will and Emery represented Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, in its agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists.

Portage acquired Tarus in exchange for 2,425,999 shares of Portage along with the assumption of $3 million of Tarus’ liabilities. Portage will gain four best-in-class assets targeting different aspects of the adenosine pathway as part of the acquisition.

The McDermott team advising Portage is led by Bob Cohen and Eric Klee and includes Alex Laznovsky, Jeronimo Soares de Sousa, Myia Williams, Dan Zucker, Michael Siekman, Brian Malkin, Anisa Mohanty, Michelle Strowhiro and Daphne Trotter.

For more details, read Portage Biotech’s full press release here.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts